Jama Author Interviews: Covering Research In Medicine, Science, & Clinical Practice. For Physicians, Researchers, & Clinician

Interview with Michael J. Barry, MD, USPSTF member and coauthor of USPSTF Recommendation: Carotid Artery Stenosis

Interview with Peter Pronovost, MD, PhD, author of Ensuring Quality in the Era of Virtual Care and Abraham Verghese, MD, author of Virtual Care and Real Connection in the Era of COVID-19

Peter Piot, MD, PhD, director of The London School of Hygiene and Tropical Medicine, is a legend in global health, having been involved in identification of HIV and Ebola virus in Africa. He was founding executive director of UNAIDS and Under Secretary-General of the United Nations from 1995 to 2008. He joins JAMA's Q&A series to discuss the global public health response to COVID-19 past, present, and future. Recorded January 28, 2021. Related Article(s): The Challenges Ahead With Monoclonal Antibodies

Interview with Frederick P. Rivara, MD, author of Three Interventions to Address the Other Pandemic—Firearm Injury and Death

President Biden has released a health care plan that proposes reducing the age of eligibility for Medicare to 60 years and introducing a public option. Larry Levitt, MPP, Executive Vice President for Health Policy at the Kaiser Family Foundation, JAMA Associate Editor Karen Joynt Maddox, MD, MPH, Co-Director of the Center for Health Economics and Policy (CHEP) at Washington University School of Medicine, and Lawrence O. Gostin, JD, from the O’Neill Institute for National and Global Health Law at Georgetown University discuss prospects for health care reform under the new administration. Recorded January 21, 2021. Related Article(s): Moving Patient Care Forward in the Biden Era

Interview with John P A Ioannidis, MD, DSC, author of Recalibrating the Use of Race in Medical Research

Incoming Centers for Disease Control and Prevention (CDC) Director Rochelle P. Walensky, MD, MPH, returns to JAMA's Q&A series to discuss her vision and priorities for the agency and changes in its pandemic response strategies, when she takes the reins on January 20. Recorded January 19, 2021. Related Article(s): All-Cause Excess Mortality and COVID-19–Related Mortality Among US Adults Aged 25-44 Years, March-July 2020

To get more vaccine to more people more efficiently, UCSF School of Medicine's Robert M. Wachter, MD, recently urged giving a single dose now and deferring the second dose until more vaccine is available. Paul A. Offit, MD, of The Children's Hospital of Philadelphia, disagrees. The two discuss the pros and the cons of the plan and alternative responses to road bumps in the US vaccine rollout, on JAMA's live Q&A series. Recorded January 19, 2021. Related Article: Developing a SARS-CoV-2 Vaccine at Warp Speed

Interview with Michael Silverstein, MD, MPH, USPSTF member and coauthor of USPSTF Recommendation: Tobacco Cessation in Adults

Interview with Raina M. Merchant, MD, author of Public Health Messaging in an Era of Social Media

Intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) both improve outcomes for patients with acute ischemic stroke. Jeffrey L. Saver, MD, director of UCLA’s Comprehensive Stroke and Vascular Neurology Program and a JAMA Associate Editor, discusses 2 randomized trials comparing outcomes for stroke patients treated with IVT prior to EVT vs EVT alone. Related Article: Intravenous Thrombolysis Before Endovascular Thrombectomy for Acute Ischemic Stroke

The COVID-19 pandemic has prompted scientists to use adaptive research designs to evaluate potential treatments simultaneously and efficiently, increasing the likelihood that patients will receive treatments most likely to be effective for them. Lennie Derde, MD, of University Medical Center Utrecht in the Netherlands and JAMA Associate Editor Christopher W. Seymour, MD, of University of Pittsburgh Medical Center join JAMA's Q&A series to discuss the latest in critical care management of COVID-19 patients and emerging treatment strategies and therapies. Recorded January 13, 2021. Related Article(s): Sensible Medicine-Optimizing the Trade-off Between Learning and Doing in a Pandemic

Arnold S. Monto, MD, chaired the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) meetings in December that led to Emergency Use Authorization (EUA) of the Pfizer/BioNTech and Moderna vaccines. He joins JAMA's Q&A series from the University of Michigan School of Public Health to discuss experience to date with the 2 products and what's next in vaccine development. Recorded January 11, 2021. Related Article(s): Experts Discuss COVID-19: Vaccine Allocation, Placebo Groups, and More

Increasing the number of physicians who are Black, Hispanic/Latinx, and Indigenous benefits everyone in the US, but it cannot be the sole responsibility of historically Black colleges and universities (HBCUs). Valerie Montgomery Rice, MD, president and dean of Morehouse School of Medicine (MSM), and Clyde W. Yancy, MD, of Northwestern Medicine, join JAMA Editor in Chief Howard Bauchner, MD, to discuss options for developing training pipelines of underrepresented minority health science students, and how academic medicine can make racial justice a part of its work and mission. Recorded January 5, 2021. Related Article: Academic Medicine and Black Lives Matter

The National Academy of Medicine's 2000 report "To Err Is Human" launched the health care quality movement in the US. Victor Dzau, MD, president of the National Academy of Medicine, and Don Berwick, MD, MPP, from the Institute for Healthcare Improvement, discuss progress to date in advancing quality and prospects for improving outcomes and reducing harms, errors, and cost in the next 20 years. Recorded December 22, 2020. Related Article(s): Two Decades Since To Err Is Human

Interview with Geoffrey S. Ginsburg, MD, PhD, author of Digital Health—The Need to Assess Benefits, Risks, and Value

With coronavirus vaccines now available, what are the timeline and prospects for "herd immunity" and return to a new normal? Marc Lipsitch, DPhil, of Harvard T.H. Chan School of Public Health returns to JAMA's Q&A series with Paul D. Biddinger, MD, director of Massachusetts General Hospital's Center for Disaster Medicine, to discuss. Recorded December 17, 2020. Related Article(s): COVID-19 Vaccines and Herd Immunity The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines Herd Immunity and Implications for SARS-CoV-2 Control Herd Immunity as a Coronavirus Pandemic Strategy

Peter W. Marks, MD, PhD, and Stephen M. Hahn, MD, return to JAMA's Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the data, the weekend's EUA designation (Pfizer/BioNTech), and the process for future full licensure and postmarketing safety surveillance. Dr Marks directs the US FDA's Center for Biologics Evaluation and Research (CBER). Dr Hahn is commissioner of the US Food and Drug Administration. Recorded December 14, 2020. Related Article(s): Behaviorally Informed Strategies for a National COVID-19 Vaccine Promotion Program

Interview with Chyke A. Doubeni, MD, MPH, USPSTF member and coauthor of USPSTF Recommendation: Screening for Hepatitis B Virus Infection in Adolescents and Adults

Anthony S. Fauci, MD, returns to JAMA's Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the public data, deliberations at Thursday's FDA Advisory Committee meeting, and prospects for an agency Emergency Use Authorization designation, licensure, and rollout. Recorded December 11, 2020. Related Article(s): Coronavirus Infections—More Than Just the Common Cold